Genmab A/S began a pivotal study of HuMax-EGFR (zalutumumab) in otherwise incurable patients with head and neck cancer, an indication that could serve as a springboard for using the human antibody more down the road.
Starting in patients who are very sick and have no other alternative the company plans to expand the product's use into first line head and neck cancer treatment and other diseases.
Patients in the study will receive an initial dose of 8mg/kg, followed by weekly infusions of maintenace doses and disease progression followed until death.
EGF stands for epidermal growth factor and tumor cells need this to sustain growth. Drugs like this are out on the market now, eg, Erbitux from Imclone, but are indicated for colon cancers.
The Copenhagen, Denmark based company saw its shares on the Copenhagen Stock Exchange (CSE:GEN lose DKK2 to close at DKK224 or $38.21. It is traded in the US as GNMSF.PK and is up to $38.25
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment